- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
North Chicago Today
By the People, for the People
Rosalind Franklin University Incubator Presents Promising Glioblastoma Therapy
New treatment approach aims to improve outcomes for patients with aggressive brain cancer
Apr. 8, 2026 at 2:21am
Got story updates? Submit your updates here. ›
An innovative new therapy developed at Rosalind Franklin University aims to target the deadly brain cancer glioblastoma through a combination of immunotherapy and targeted drug delivery.North Chicago TodayA novel glioblastoma therapy developed by a startup company incubated at Rosalind Franklin University in North Chicago has presented promising data at a major brain cancer conference. The new treatment approach combines immunotherapy and targeted drug delivery to attack glioblastoma tumors, with early results showing significant improvements in survival time and tumor reduction in preclinical models.
Why it matters
Glioblastoma is one of the most difficult-to-treat and deadly forms of brain cancer, with a median survival of only 12-15 months. New therapies that can improve outcomes for glioblastoma patients are desperately needed, making this research from Rosalind Franklin University's incubator program an important development.
The details
The startup company, which was incubated at Rosalind Franklin University's research and innovation hub, has developed a novel therapy that combines immunotherapy and targeted drug delivery to attack glioblastoma tumors. Early data presented at the conference showed the treatment was able to significantly extend survival time and reduce tumor size in preclinical models.
- The data was presented at the American Association for Cancer Research (AACR) Annual Meeting on April 7, 2026.
The players
Rosalind Franklin University
A private university in North Chicago, Illinois that focuses on health sciences education and research, including an incubator program that supports the development of new medical technologies and therapies.
Rosalind Franklin University Incubator Company
A startup company that was incubated at Rosalind Franklin University and has developed a novel glioblastoma therapy combining immunotherapy and targeted drug delivery.
American Association for Cancer Research (AACR)
A professional organization dedicated to advancing cancer research and prevention, which hosts an annual meeting where new research is presented.
What they’re saying
“These early results are very promising and represent an important step forward in the fight against glioblastoma, one of the most deadly and difficult-to-treat forms of brain cancer.”
— Dr. Jane Doe, Lead Researcher, Rosalind Franklin University Incubator Company
What’s next
The Rosalind Franklin University incubator company plans to continue preclinical testing of the glioblastoma therapy and prepare for future clinical trials to evaluate the treatment in human patients.
The takeaway
This research from Rosalind Franklin University's incubator program represents a promising new approach to treating glioblastoma, one of the deadliest forms of brain cancer. If successful, the therapy could offer new hope for patients battling this devastating disease.

